Author: Angelina Bisconte, Scientific Information Developer, Precision For Medicine Title: Precision in the Detection of Myeloid-derived Suppressor Cells (MDSCs)
May 1-3, 2017 San Diego, CA Booth #516 Precision for Medicine will be exhibiting at the National Biotechnology Conference in San Diego. […]
April 11-12, 2017 Burlingame, CA Precision Oncology will be exhibiting and presenting a session at Arena’s Clinical Operations in Oncology Trials – West Coast conference in Burlingame, CA. Session on April 11ᵗʰ : Jeff Seroskie, MS, Vice President, Precision Oncology will be speaking on how “Precision medicine is ‘bending the curve’ of drug development” in oncology.
The laboratory developed test (LDT) has proven to be a flexible, quick, lower-investment assay commercialization option—yet the evolving regulatory landscape still threatens to alter that.
In this high-stakes, high-velocity environment of oncology drug development and regulatory approval, biotech companies face significant competitive pressure to move quickly from first-in-human to proof-of-concept.
Today’s clinical trials generate and capture hundreds of thousands of data points—spanning multiple types of biomarker data generated by multiple vendors and diverse assays.
Precision Oncology’s Dr. Gerald Messerschimdt discusses clinical protocol development with Denise Myshko for PharmaVOICE.
Precision for Medicine’s Scott Marshall and Jared Kohler
February 20-24, 2017 San Francisco, CA Booth #201 Precision for Medicine will be exhibiting at Molecular Medicine Tri-Con 2017 from February 20-24, at the Moscone North Convention Center in San Francisco, CA. […]
February 9- 10, 2017 San Diego, CA Precision for Medicine will be exhibiting and David Parker, PhD, SVP, Diagnostics Solutions, will be presenting a case study at the Q1 Dx Coverage & Reimbursement conference from February 9-10, at the Andaz San Diego.